Insider · CIK 0001310683
Brian M Culley
Files at LCTX (Lineage Cell Therapeutics, Inc.). First filing May 28, 2024, latest Mar 12, 2026.
In brief
Brian M Culley files SEC Form 4 as CEO, president and director at LCTX (Lineage Cell Therapeutics, Inc.). Since May 28, 2024, Brian M Culley has reported 3 open-market buys worth $59k and 0 open-market sells worth $0, the latest filed on Mar 12, 2026.
A track record needs three past buys with six months of prices behind them; Brian M Culley has 2, so none is measured yet.
The newest scored trade: bought $24k of LCTX on Mar 12, 2026, filed Mar 12, 2026, scored 32 (weak). In the last 12 months: 1 buy worth $24k and 0 sells worth $0.
Where the trades landed
Last year at the company this insider has traded most, with each buy and sell on the bar it happened.
LCTX: Lineage Cell Therapeutics, Inc.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value. Click a marked bar to open the signal.Charts by TradingView Lightweight Charts™
Signals
This insider’s open-market buys and sells, scored.
| Score | Company | Value | Holdings | Price context | Filed |
|---|---|---|---|---|---|
| 32Weak | LCTXbuy Lineage Cell Therapeutics, Inc. | $24k 15,000 shares | +6% | +305% from low-19% from high | |
| 46Moderate | Lineage Cell Therapeutics, Inc. | $24k 40,000 shares | +26% | - | |
| 36Weak | LCTXbuy Lineage Cell Therapeutics, Inc. | $11k 10,000 shares | +7% | +22% from low-31% from high |
Transactions
Every row this insider has filed, 17 in all, newest first.
| Date | Company | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Mar 12, 2026 | LCTX Lineage Cell Therapeutics, Inc. | POpen-market purchase Common Shares | +15,000 | $1.63 | $24k | 255,516 | Mar 12, 2026 |
| Mar 5, 2026 | LCTX Lineage Cell Therapeutics, Inc. | AGrant or award Employee Stock Option (Right to Buy)derivative | +3,250,000 | $0.00 | $0 | 3,250,000 | Mar 6, 2026 |
| Feb 11, 2026 | LCTX Lineage Cell Therapeutics, Inc. | MOption exercise Common Shares | +31,250 | - | - | 253,385 | Feb 13, 2026 |
| Feb 11, 2026 | LCTX Lineage Cell Therapeutics, Inc. | FTax withholding Common Shares | -12,869 | $1.80 | $23k | 240,516 | Feb 13, 2026 |
| Feb 11, 2026 | LCTX Lineage Cell Therapeutics, Inc. | MOption exercise Restricted Stock Unitsderivative | -31,250 | $0.00 | $0 | 0 | Feb 13, 2026 |
| Dec 19, 2025 | LCTX Lineage Cell Therapeutics, Inc. | AGrant or award Common Shares | +8,925 | - | - | 222,469 | Dec 19, 2025 |
| Dec 19, 2025 | LCTX Lineage Cell Therapeutics, Inc. | FTax withholding Common Shares | -334 | $1.68 | $561 | 222,135 | Dec 19, 2025 |
| Mar 10, 2025 | LCTX Lineage Cell Therapeutics, Inc. | AGrant or award Employee Stock Option (Right to Buy)derivative | +2,300,000 | $0.00 | $0 | 2,300,000 | Mar 12, 2025 |
| Feb 11, 2025 | LCTX Lineage Cell Therapeutics, Inc. | MOption exercise Common Shares | +31,249 | - | - | 226,091 | Feb 12, 2025 |
| Feb 11, 2025 | LCTX Lineage Cell Therapeutics, Inc. | FTax withholding Common Shares | -12,547 | $0.65 | $8,156 | 213,544 | Feb 12, 2025 |
| Feb 11, 2025 | LCTX Lineage Cell Therapeutics, Inc. | MOption exercise Restricted Stock Unitsderivative | -31,249 | $0.00 | $0 | 31,250 | Feb 12, 2025 |
| Nov 21, 2024 | LCTX Lineage Cell Therapeutics, Inc. | POpen-market purchase Common Shares | +40,000 | $0.60 | $24k | 194,842 | Nov 22, 2024 |
| May 24, 2024 | LCTX Lineage Cell Therapeutics, Inc. | POpen-market purchase Common Shares | +10,000 | $1.05 | $11k | 154,842 | May 28, 2024 |
| Mar 7, 2024 | LCTX Lineage Cell Therapeutics, Inc. | AGrant or award Employee Stock Option (Right to Buy)derivative | +1,900,000 | $0.00 | $0 | 1,900,000 | Mar 8, 2024 |
| Feb 11, 2024 | LCTX Lineage Cell Therapeutics, Inc. | MOption exercise Common Shares, no par value | +31,249 | - | - | 157,648 | Feb 12, 2024 |
| Feb 11, 2024 | LCTX Lineage Cell Therapeutics, Inc. | FTax withholding Common Shares, no par value | -12,806 | $1.08 | $14k | 144,842 | Feb 12, 2024 |
| Feb 11, 2024 | LCTX Lineage Cell Therapeutics, Inc. | MOption exercise Restricted Stock Unitsderivative | -31,249 | $0.00 | $0 | 62,499 | Feb 12, 2024 |
Questions about Brian M Culley
Answered from the filings on this page, as of the latest one.
Is Brian M Culley buying or selling?
In the last 12 months Brian M Culley reported 1 open-market buy worth $24k and 0 open-market sells worth $0 on SEC Form 4; the latest was bought $24k of LCTX on Mar 12, 2026. Grants, option exercises and tax withholding are not counted.
How did Brian M Culley's past buys perform?
Not measured yet. InsiderTell needs three past buys with six months of prices to publish a track record, and Brian M Culley has 2.
Where does Brian M Culley file Form 4?
Brian M Culley has filed Form 4 at LCTX (Lineage Cell Therapeutics, Inc.) as President and CEO. A Form 4 is required of officers, directors and holders of more than 10% of a share class within two business days of a trade.
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.